AOD-9604 vs 5-Amino-1MQ
Both AOD-9604 and 5-Amino-1MQ are used for fat-loss. Here's how their evidence, dosing, and regulatory status actually compare.
AOD-9604
Evidence C+Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
View full AOD-9604 profile →5-Amino-1MQ
Evidence C+5-Amino-1-Methylquinolinium
A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.
View full 5-Amino-1MQ profile →Side-by-Side
| Attribute | AOD-9604 | 5-Amino-1MQ |
|---|---|---|
| Evidence Grade | C+ | C+ |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — small-molecule research compound (NNMT inhibitor) |
| Typical Dose | 250–500 mcg daily (subcutaneous) | 50–150 mg orally daily (research-only) |
| Clinics Indexed | 134 | 31 |
| Categories | weight-loss, fat-loss | fat-loss, longevity |
Key reported benefits — AOD-9604
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Key reported benefits — 5-Amino-1MQ
- ✓NNMT inhibition
- ✓Fat-mass reduction (preclinical)
- ✓Muscle stem-cell support
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.